A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy

Atherosclerosis Supplements

Volumn 19, Issue , 2015, Pages 1-12

  Aguiar, Carlos ^a   Alegria, Eduardo ^b   Bonadonna, Riccardo C ^c   Catapano, Alberico L ^d   Cosentino, Francesco ^e   Elisaf, Moses ^f   Farnier, Michel ^g   Ferrières, Jean ^h   Filardi, Pasquale Perrone ⁱ   Hancu, Nicolae ^j   Kayikcioglu, Meral ^k   Mello e Silva, Alberto ^l   Millan, Jesus ^m   Reiner, Željko ⁿ   Tokgozoglu, Lale ^o   Valensi, Paul ^p   Viigimaa, Margus ^q   Vrablik, Michal ^r   Zambon, Alberto ^s   Zamorano, José Luis ^t   Ferrari, Roberto ^u   more..

^a HOSPITAL DE SANTA CRUZ   (Portugal)

^b Interventional Cardiology Department   (Spain)

^c UNIVERSITY OF PARMA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF IOANNINA   (Greece)

^g Point Medical   (France)

^h UNIVERSITÉ PAUL SABATIER   (France)

ⁱ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^j IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^k EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^l HOSPITAL EGAS MONIZ   (Portugal)

^m HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

ⁿ UNIVERSITY OF ZAGREB   (Croatia)

^o HACETTEPE UNIVERSITY   (Turkey)

^p UNIVERSITÉ PARIS 13   (France)

^q TALLINN UNIVERSITY OF TECHNOLOGY   (Estonia)

^r CHARLES UNIVERSITY   (Czech Republic)

^s UNIVERSITY OF PADOVA   (Italy)

^t UNIVERSITY OF ALCALÁ   (Spain)

^u UNIVERSITY HOSPITAL OF FERRARA   (Italy)

more..

Author keywords

Atherogenic dyslipidaemia; Cardiovascular risk; Cholesterol; Combination therapy; Fenofibrate; Statins; Triglycerides

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CREATININE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; ANTILIPEMIC AGENT; LIPID;

ACUTE CORONARY SYNDROME; ANTIHYPERTENSIVE THERAPY; ARTICLE; ATHEROGENIC DYSLIPIDEMIA; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIAC AUTONOMIC NEUROPATHY; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL TRANSPORT; CLINICAL STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSLIPIDEMIA; GENETIC VARIABILITY; GLUCOSE METABOLISM; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; MACROALBUMINURIA; METABOLIC SYNDROME X; MONOTHERAPY; PRIORITY JOURNAL; RISK MANAGEMENT; RISK REDUCTION; TRANSIENT ISCHEMIC ATTACK; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS; BLOOD; CARDIOVASCULAR DISEASES; COMBINATION DRUG THERAPY; COMPLICATION; CONSENSUS DEVELOPMENT; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; EUROPE; FRANCE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; EUROPE; FENOFIBRATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; LIPIDS; PARIS;

EID: 84939806481     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/S1567-5688(15)30001-5     Document Type: Article

References (90)

1. Austin M.A., King M.C., Vranizan K.M., Krauss R.M. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990 Aug, 82(2):495-506.
2. Austin M.A., Breslow J.L., Hennekens C.H., Buring J.E., Willett W.C., Krauss R.M. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988 Oct 7, 260(13):1917-1921.
3. Musunuru K., Orho-Melander M., Caulfield M.P., Li S., Salameh W.A., Reitz R.E., et al. Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk. Arterioscler Thromb Vasc Biol 2009 Nov, 29(11):1975-1980.
4. Capell W.H., Zambon A., Austin M.A., Brunzell J.D., Hokanson J.E. Compositional differences of LDL particles in normal subjects with LDL subclass phenotype A and LDL subclass phenotype B. Arterioscler Thromb Vasc Biol 1996 Aug, 16(8):1040-1046.
5. Mikhailidis D.P., Elisaf M., Rizzo M., Berneis K., Griffin B., Zambon A., et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011 Sep, 9(5):533-571.
6. Chapman M.J., Ginsberg H.N., Amarenco P., Andreotti F., Borén J., Catapano A.L., et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011 Jun, 32(11):1345-1361.
7. Leiter L.A., Lundman P., da Silva P.M., Drexel H., Jünger C., Gitt A.K. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med 2011 Nov, 28(11):1343-1351.
8. Pedro-Botet J., Flores-Le Roux J.A., Mostaza J.M., Pintó X., de la Cruz J.J., Banegas J.R. Atherogenic dyslipidemia: prevalence and management in lipid clinics. Rev Clin Esp 2014 Dec, 214(9):491-498.
9. Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia - full report. J Clin Lipidol 2014 Jan, 8(1):29-60.
10. Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., Bhala N., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010 Nov 13, 376(9753):1670-1681.
11. Reiner Z., Catapano A.L., De Backer G., Graham I., Taskinen M.R., Wiklund O., et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011 Jul, 32(14):1769-1818.
12. Voight B.F., Peloso G.M., Orho-Melander M., Frikke-Schmidt R., Barbalic M., Jensen M.K., et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012 Aug 11, 380(9841):572-580.
13. Toth P.P., Barter P.J., Rosenson R.S., Boden W.E., Chapman M.J., Cuchel M., et al. High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol 2013 Sep, 7(5):484-525.
14. Camont L., Chapman M.J., Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med 2011 Oct, 17(10):594-603.
15. Kontush A. HDL-mediated mechanisms of protection in cardiovascular disease. Cardiovasc Res 2014 Aug 1, 103(3):341-349.
16. Waldman B., Jenkins A.J., Davis T.M., Taskinen M.R., Scott R., O'Connell R.L., et al. HDL-C and HDL-C/ApoA-I predict long-term progression of glycemia in established type 2 diabetes. Diabetes Care 2014 Aug, 37(8):2351-2358.
17. Kostapanos M.S., Elisaf M.S. High density lipoproteins and type 2 diabetes: emerging concepts in their relationship. World J Exp Med 2014 Feb 20, 4(1):1-6.
18. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 Oct 8, 366(9493):1267-1278.
19. Kearney P.M., Blackwell L., Collins R., Keech A., Simes J., Peto R., et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008 Jan 12, 371(9607):117-125.
20. Reiner Z., De Bacquer D., Kotseva K., Prugger C., De Backer G., Wood D. Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey. Atherosclerosis 2013 Dec, 231(2):300-307.
21. Genest J.J., McNamara J.R., Salem D.N., Schaefer E.J. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 1991 Jun 1, 67(15):1185-1189.
22. Faergeman O., Holme I., Fayyad R., Bhatia S., Grundy S.M., Kastelein J.J., et al. Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. Am J Cardiol 2009 Aug 15, 104(4):459-463.
23. Miller M., Cannon C.P., Murphy S.A., Qin J., Ray K.K., Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008 Feb 19, 51(7):724-730.
24. Ginsberg H.N., Elam M.B., Lovato L.C., Crouse J.R., Leiter L.A., Linz P., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010 Apr 29, 362(17):1563-1574.
25. Carey V.J., Bishop L., Laranjo N., Harshfield B.J., Kwiat C., Sacks F.M. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol 2010 Sep 15, 106(6):757-763.
26. Bayturan O., Kapadia S., Nicholls S.J., Tuzcu E.M., Shao M., Uno K., et al. Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. J Am Coll Cardiol 2010 Jun 15, 55(24):2736-2742.
27. Andersson C., Lyass A., Vasan R.S., Massaro J.M., D'Agostino R.B., Robins S.J. Long-term risk of cardiovascular events across a spectrum of adverse major plasma lipid combinations in the Framingham Heart Study. Am Heart J 2014 Dec, 168(6):878-883.
28. Nordestgaard B.G., Varbo A. Triglycerides and cardiovascular disease. Lancet 2014 Aug 16, 384(9943):626-635.
29. Nordestgaard B.G., Benn M., Schnohr P., Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007 Jul 18, 298(3):299-308.
30. Freiberg J.J., Tybjaerg-Hansen A., Jensen J.S., Nordestgaard B.G. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008 Nov 12, 300(18):2142-2152.
31. Schwartz G.G., Abt M., Bao W., DeMicco D., Kallend D., Miller M., et al. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol 2015 Jun 2, 65(21):2267-2275.
32. Reiner Z. Are elevated serum triglycerides really a risk factor for coronary artery disease?. Cardiology 2015 May 12, 131(4):225-227.
33. Di Angelantonio E., Sarwar N., Perry P., Kaptoge S., Ray K.K., Thompson A., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009 Nov 11, 302(18):1993-2000.
34. Sirimarco G., Labreuche J., Bruckert E., Goldstein L.B., Fox K.M., Rothwell P.M., et al. Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. Stroke 2014 May, 45(5):1429-1436.
35. Barter P., Gotto A.M., LaRosa J.C., Maroni J., Szarek M., Grundy S.M., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007 Sep 27, 357(13):1301-1310.
36. Shaikh M., Wootton R., Nordestgaard B.G., Baskerville P., Lumley J.S., La Ville A.E., et al. Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans. Arterioscler Thromb 1991 May, 11(3):569-577.
37. Nordestgaard B.G., Tybjaerg-Hansen A., Lewis B. Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants. Arterioscler Thromb 1992 Jan, 12(1):6-18.
38. Nordestgaard B.G., Wootton R., Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol 1995 Apr, 15(4):534-542.
39. Varbo A., Benn M., Tybjærg-Hansen A., Jørgensen A.B., Frikke-Schmidt R., Nordestgaard B.G. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013 Jan 29, 61(4):427-436.
40. Jørgensen A.B., Frikke-Schmidt R., West A.S., Grande P., Nordestgaard B.G., Tybjærg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J 2013 Jun, 34(24):1826-1833.
41. Reyes-Soffer G., Ngai C.I., Lovato L., Karmally W., Ramakrishnan R., Holleran S., et al. Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. Diabetes Care 2013 Feb, 36(2):422-428.
42. Zambon A., Zhao X.Q., Brown B.G., Brunzell J.D. Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease. Am J Cardiol 2014 May 1, 113(9):1494-1498.
43. Perk J., De Backer G., Gohlke H., Graham I., Reiner Z., Verschuren M., et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012 Jul, 33(13):1635-1701.
44. Boekholdt S.M., Arsenault B.J., Mora S., Pedersen T.R., LaRosa J.C., Nestel P.J., et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012 Mar 28, 307(12):1302-1309.
45. Zambon A., Puato M., Faggin E., Grego F., Rattazzi M., Pauletto P. Lipoprotein remnants and dense LDL are associated with features of unstable carotid plaque: a flag for non-HDL-C. Atherosclerosis 2013 Sep, 230(1):106-109.
46. Koster I., Huppertz E., Hauner H., Schubert I. Costs of Diabetes Mellitus (CoDiM) in Germany, direct per-capita costs of managing hyperglycaemia and diabetes complications in 2010 compared to 2001. Exp Clin Endocrinol Diabetes 2014 Oct, 122(9):510-516.
47. Pelletier E.M., Shim B., Ben-Joseph R., Caro J.J. Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis. Pharmacoeconomics 2009, 27(6):479-490.
48. Gordois A., Scuffham P., Shearer A., Oglesby A., Tobian J.A. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 2003 Jun, 26(6):1790-1795.
49. Tesfaye S., Boulton A.J., Dyck P.J., Freeman R., Horowitz M., Kempler P., et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010 Oct, 33(10):2285-2293.
50. Fioretto P., Dodson P.M., Ziegler D., Rosenson R.S. Residual microvascular risk in diabetes: unmet needs and future directions. Nat Rev Endocrinol 2010 Jan, 6(1):19-25.
51. The Royal College of Ophthalmologists. Diabetic Retinopathy Guidelines 2015 Dec.
52. Murray C.J., Vos T., Lozano R., Naghavi M., Flaxman A.D., Michaud C., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012 Dec 15, 380(9859):2197-2223.
53. Reiner Z. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Nutr Metab Cardiovasc Dis 2013 Sep, 23(9):799-807.
54. Fruchart J.C., Sacks F., Hermans M.P., Assmann G., Brown W.V., Ceska R., et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008 Nov 17, 102(10 Suppl):1K-34K.
55. Fruchart J.C., Sacks F.M., Hermans M.P., Assmann G., Brown W.V., Ceska R., et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res 2008 Nov, 5(4):319-335.
56. Valensi P., Picard S. Lipids, lipid-lowering therapy and diabetes complications. Diabetes Metab 2011 Feb, 37(1):15-24.
57. Zoppini G., Negri C., Stoico V., Casati S., Pichiri I., Bonora E. Triglyceride-high-density lipoprotein cholesterol is associated with microvascular complications in type 2 diabetes mellitus. Metabolism 2012 Jan, 61(1):22-29.
58. Morton J., Zoungas S., Li Q., Patel A.A., Chalmers J., Woodward M., et al. Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE study. Diabetes Care 2012 Nov, 35(11):2201-2206.
59. Sacks F.M., Hermans M.P., Fioretto P., Valensi P., Davis T., Horton E., et al. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation 2014 Mar 4, 129(9):999-1008.
60. Callaghan B.C., Feldman E., Liu J., Kerber K., Pop-Busui R., Moffet H., et al. Triglycerides and amputation risk in patients with diabetes: ten-year follow-up in the DISTANCE study. Diabetes Care 2011 Mar, 34(3):635-640.
61. Wiggin T.D., Sullivan K.A., Pop-Busui R., Amato A., Sima A.A., Feldman E.L. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 2009 Jul, 58(7):1634-1640.
62. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H., Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003 Jan 30, 348(5):383-393.
63. Ballantyne C.M. Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol 1998 Nov 5, 82(9A):3Q-12Q.
64. Catapano A.L., Farnier M., Foody J.M., Toth P.P., Tomassini J.E., Brudi P., et al. Combination therapy in dyslipidemia: where are we now?. Atherosclerosis 2014 Nov, 237(1):319-335.
65. O'Keefe J.H., Cordain L., Harris W.H., Moe R.M., Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 2004 Jun 2, 43(11):2142-2146.
66. Fulcher J., O'Connell R., Voysey M., Emberson J., Blackwell L., Mihaylova B., et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015 Apr 11, 385(9976):1397-1405.
67. Cannon C.P., Blazing M.A., Giugliano R.P., McCagg A., White J.A., Theroux P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015 Jun 18, 372(25):2387-2397.
68. Fruchart J.C., Davignon J., Hermans M.P., Al-Rubeaan K., Amarenco P., Assmann G., et al. Residual macrovascular risk in 2013: what have we learned?. Cardiovasc Diabetol 2014 Jan 24, 13:26.
69. Reiner Z. Combined therapy in the treatment of dyslipidemia. Fundam Clin Pharmacol 2010 Feb, 24(1):19-28.
70. McKeage K., Keating G.M. Fenofibrate: a review of its use in dyslipidaemia. Drugs 2011 Oct 1, 71(14):1917-1946.
71. Grundy S.M., Vega G.L., Yuan Z., Battisti W.P., Brady W.E., Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005 Feb 15, 95(4):462-468.
72. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005 Nov 26, 366(9500):1849-1861.
73. Ting R., Keech A. Fenofibrate and renal disease: clinical effects in diabetes. Clin Lipidol 2013, 8(6):669-680.
74. Scott R., O'Brien R., Fulcher G., Pardy C., d'Emden M., Tse D., et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009 Mar, 32(3):493-498.
75. Chew E.Y., Ambrosius W.T., Davis M.D., Danis R.P., Gangaputra S., Greven C.M., et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010 Jul 15, 363(3):233-244.
76. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee 2011 May 19.
77. Sacks F.M., Carey V.J., Fruchart J.C. Combination lipid therapy in type 2 diabetes. N Engl J Med 2010 Aug 12, 363(7):692-694.
78. Ray K.K., Kastelein J.J., Boekholdt S.M., Nicholls S.J., Khaw K.T., Ballantyne C.M., et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 2014 Apr, 35(15):960-968.
79. European Medicines Agency (EMA) Assessment report for fenofibrate, bezafibrate, ciprofibrate, and gemfibrozil containing medical products 2011 Feb 28.
80. Prueksaritanont T., Tang C., Qiu Y., Mu L., Subramanian R., Lin J.H. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002 Nov, 30(11):1280-1287.
81. Krysiak R., Stachura-Kulach A., Okopien B. Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances. Pharmacol Rep 2010 Jan, 62(1):120-130.
82. Wysocki J., Belowski D., Kalina M., Kochanski L., Okopien B., Kalina Z. Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. Int J Clin Pharmacol Ther 2004 Apr, 42(4):212-217.
83. Mychaleckyj J.C., Craven T., Nayak U., Buse J., Crouse J.R., Elam M., et al. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care 2012 May, 35(5):1008-1014.
84. Davis T.M., Ting R., Best J.D., Donoghoe M.W., Drury P.L., Sullivan D.R., et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011 Feb, 54(2):280-290.
85. Bonds D.E., Craven T.E., Buse J., Crouse J.R., Cuddihy R., Elam M., et al. Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia 2012 Jun, 55(6):1641-1650.
86. Preiss D., Tikkanen M.J., Welsh P., Ford I., Lovato L.C., Elam M.B., et al. Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA 2012 Aug 22, 308(8):804-811.
87. Maningat P., Gordon B.R., Breslow J.L. How do we improve patient compliance and adherence to long-term statin therapy?. Curr Atheroscler Rep 2013 Jan, 15(1):291.
88. Schedlbauer A., Davies P., Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev 2010 Mar 17, 3:CD004371.
89. Degli Esposti L., Saragoni S., Batacchi P., Benemei S., Geppetti P., Sturani A., et al. Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis. Clin Ther 2012 Jan, 34(1):190-199.
90. Blonde L., Wogen J., Kreilick C., Seymour A.A. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab 2003 Nov, 5(6):424-431.